
 W P S E R E I
 (TM)

Release 3.1A John F. Collins, Biocomputing Research Unit.
 Copyright (c) 1993-1998 University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

MSrch_DP protein - protein database search, using Smith-Waterman algorithm
 Run on: Sat May 13 09:05:14 2000; Maspar time 3.28 Seconds
 Tabular output not generated. 166.295 Million cell updates/sec

Title: >US-09-331-631-25
 Description: (1-23) from US09331631.pep
 Perfect Score: 177
 Sequence: 1 MMRARFPLLLGLVFLASVSF 23

Scoring table: PAM 150
 Gap 11

Searched: 188963 seqs, 23686106 residues

Post-processing: Minimum Match 0%
 Listing first 45 summaries

Database: a-geneseq35
 1:geneseqp

Statistics: Mean 22.674; Variance 109.644; scale 0.207

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description	Pred. No.
1	177	100.0	605	1 W62838	Glycine max antimicrob	1.02e-06
2	138	78.0	23	1 R27003	Phaseolin signal seque	1.34e-03
3	83	46.9	660	1 W93391	Human HEV ORF 2 protei	1.96e+01
4	82	46.3	659	1 W93387	Human HEV ORF 2 protei	2.31e+01
5	82	46.3	659	1 R39308	Mexico strain HEV ORF2	2.31e+01
6	82	46.3	659	1 R38787	HEV ORF2 protein.	2.31e+01
7	82	46.3	659	1 W35827	Hepatitis E virus Mexi	2.31e+01
8	82	46.3	660	1 R96090	Hepatitis E virus (Mex	2.31e+01
9	81	45.8	105	1 W50882	Amino acid sequence of	2.73e+01
10	81	45.8	614	1 W62834	Arachis hypogaea antim	2.73e+01
11	81	45.8	614	1 W22149	Peanut allergen Ara hi	2.73e+01
12	81	45.8	626	1 W22150	Secretin receptor.	3.21e+01
13	80	45.2	449	1 R30187	H. pylori GHPD 343 pro	5.23e+01
14	77	43.5	246	1 W98638	Human HEV ORF 2 protei	5.23e+01
15	77	43.5	660	1 W93390	Human HEV ORF 2 protei	5.23e+01
16	77	43.5	660	1 W93392	Human HEV ORF 2 protei	5.23e+01
17	77	43.5	660	1 W93388	Human HEV ORF 2 protei	5.23e+01
18	77	43.5	660	1 W71210	Protein encoded by ORF	5.23e+01
19	77	43.5	660	1 R36089	Hepatitis E virus (Bur	5.23e+01
20	77	43.5	660	1 R51265	HEV strain protein enc	5.23e+01
21	77	43.5	660	1 R91814	Hepatitis E virus stra	5.23e+01
22	77	43.5	660	1 R70323	Hepatitis E virus ORF2	5.23e+01
23	77	43.5	660	1 W93389	Human HEV ORF 2 protei	5.23e+01

ID	Score	Query Match	Length	ID	Description	Pred. No.
24	77	43.5	660	1 W93395	Human HEV ORF 2 protei	5.23e+01
25	77	43.5	660	1 W93394	Human HEV ORF 2 protei	5.23e+01
26	77	43.5	660	1 W93386	Human HEV ORF 2 protei	5.23e+01
27	77	43.5	660	1 W63659	Hepatitis E virus holi	5.23e+01
28	77	43.5	660	1 W35826	Hepatitis E virus Burm	5.23e+01
29	77	43.5	660	1 W80157	HEV ORF2 protein.	5.23e+01
30	77	43.5	660	1 R39306	Burma strain HEV ORF2	5.23e+01
31	77	43.5	660	1 R32825	Hepatitis E virus (HEV	5.23e+01
32	77	43.5	660	1 R14519	Protein encoded by ORF	5.23e+01
33	77	43.5	660	1 R14519	Staphylococcus aureus	6.15e+01
34	76	42.9	283	1 W89755	Human 5' EST secreted	7.23e+01
35	75	42.4	111	1 Y11987	Prostate specific redu	7.23e+01
36	75	42.4	316	1 W03198	NANB hepatitis virus H	9.97e+01
37	75	42.4	365	1 R38285	NANB hepatitis virus H	9.97e+01
38	73	41.2	365	1 R38286	NANB hepatitis virus H	9.97e+01
39	73	41.2	303	1 R33538	NANBH virus strain HC-	1.17e+02
40	72	40.7	48	1 W74777	Human secreted protein	1.17e+02
41	72	40.7	199	1 W10656	Rat GM2 activator prot	1.37e+02
42	71	40.1	996	1 W33624	Elmeria tenella 45 kDa	1.37e+02
43	71	40.1	998	1 P93706	Sequence of the antibo	1.37e+02
44	71	40.1	998	1 W33621	Elmeria tenella 45 kDa	1.61e+02
45	70	39.5	227	1 W80681	S. pneumoniae protein	1.61e+02

ALIGNMENTS

ID	Score	Query Match	Length	ID	Description	Pred. No.
1	177	100.0%	605	1 W62838	standard: Protein; 605 AA.	
2	138	78.0%	23	1 R27003	Phaseolin signal seque	
3	83	46.9%	660	1 W93391	Human HEV ORF 2 protei	
4	82	46.3%	659	1 W93387	Human HEV ORF 2 protei	
5	82	46.3%	659	1 R39308	Mexico strain HEV ORF2	
6	82	46.3%	659	1 R38787	HEV ORF2 protein.	
7	82	46.3%	659	1 W35827	Hepatitis E virus Mexi	
8	82	46.3%	660	1 R96090	Hepatitis E virus (Mex	
9	81	45.8%	105	1 W50882	Amino acid sequence of	
10	81	45.8%	614	1 W62834	Arachis hypogaea antim	
11	81	45.8%	614	1 W22149	Peanut allergen Ara hi	
12	81	45.8%	626	1 W22150	Secretin receptor.	
13	80	45.2%	449	1 R30187	H. pylori GHPD 343 pro	
14	77	43.5%	246	1 W98638	Human HEV ORF 2 protei	
15	77	43.5%	660	1 W93390	Human HEV ORF 2 protei	
16	77	43.5%	660	1 W93392	Human HEV ORF 2 protei	
17	77	43.5%	660	1 W93388	Human HEV ORF 2 protei	
18	77	43.5%	660	1 W71210	Protein encoded by ORF	
19	77	43.5%	660	1 R36089	Hepatitis E virus (Bur	
20	77	43.5%	660	1 R51265	HEV strain protein enc	
21	77	43.5%	660	1 R91814	Hepatitis E virus stra	
22	77	43.5%	660	1 R70323	Hepatitis E virus ORF2	
23	77	43.5%	660	1 W93389	Human HEV ORF 2 protei	

PT High sulphur plant seed protein gene - useful for over-expression
PT of high methionine seed storage protein in e.g. corn or soybean
PT or microorganisms
PS Example: Page 45; 98pp; English.
CC The sequence is that of the phaseolin signal sequence which was used
CC in the construction of chimeric HS2 where the native monocot signal
CC sequence of HS2 is replaced with a dicot signal sequence from phaseolin.
CC The chimeric protein can be over expressed in crop plants e.g. corn and
CC soybean which is useful for the nutritional improvement of sulphur-amino
CC acid deficient plants. See also Q28277-Q28289 and Q34797.
SQ Sequence 23 AA;

Db 1 MRRARFLLGLGVFLASVSF 23
1 MRRARFLLGLGVFLASVSF 23
QY 1 MRRARFLLGLGVFLASVSF 23

RESULT 3
ID W93391 standard; Protein: 660 AA.
AC W93391.
DT 11-JUN-1999 (first entry)
DE Human HEV ORF 2 protein from strain Ugh179.
KW Swine hepatitis E virus; HEV; cross-reaction; antibody; human; therapy;
KW vaccine; immunise; infection; detection; diagnosis; prevention.
OS Hepatitis E virus.
PN WO9904029-A2.
PD 28-JAN-1999.
PF 17-JUL-1998; 014665.
PR 18-JUL-1997; US-053069.
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
PI Emerson SU, Meng X, Purcell RH;
DR WPI: 99-132270/11.
PT New isolated swine hepatitis E virus - used to develop products for
PT the diagnosis, prevention and treatment of hepatitis E virus
PT infection in mammals; particularly humans
PS Example 1; Fig 3A; 70pp; English.
CC This invention describes a swine hepatitis E virus (HEV) and its natural
CC mutants which are capable of cross-reacting with antibodies reactive
CC with a human HEV strain or natural mutants. The HEV and the proteins
CC HEV can be used in vaccines for immunising against HEV infection. The swine
CC swine HEV can also be used as a therapeutic treatment for infection by
CC other strains of HEV. The swine HEV can also be used for the production
CC of antibodies which can be used in therapy, detection and diagnosis. The
CC products can also be used for determining the susceptibility of cells or
CC organs to infection with swine HEV. The swine HEV is particularly useful
CC for the development of agents for the prevention, treatment and detection
CC of human HEV because it is not a human virus and thus can be handled both
CC experimentally and clinically without fear of severe infection and/or
CC contamination.
SQ Sequence 660 AA;

Query Match 46.9%; Score 83; DB 1; Length 660;
Best Local Similarity 52.4%; Pred. No. 1.96e+01;
Matches 11; Conservative 6; Mismatches 3; Indels 1; Gaps 1;

Db 1 MRRP-PLLLLMFLPYVPAP 20
2 MRRARFLLGLGVFLASVSF 22
QY 2 MRRARFLLGLGVFLASVSF 22

RESULT 4
ID W93387 standard; Protein: 659 AA.
AC W93387.
DT 11-JUN-1999 (first entry)
DE Human HEV ORF 2 protein from strain Mexico.
KW Swine hepatitis E virus; HEV; cross-reaction; antibody; human; therapy;
KW vaccine; immunise; infection; detection; diagnosis; prevention.
OS Hepatitis E virus.

PN WO9904029-A2.
PD 28-JAN-1999.
PF 17-JUL-1998; 014665.
PR 18-JUL-1997; US-053069.
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
PI Emerson SU, Meng X, Purcell RH;
DR WPI: 99-132270/11.
PT New isolated swine hepatitis E virus - used to develop products for
PT the diagnosis, prevention and treatment of hepatitis E virus
PT infection in mammals; particularly humans
PS Example 1; Fig 3A; 70pp; English.
CC This invention describes a swine hepatitis E virus (HEV) and its natural
CC mutants which are capable of cross-reacting with antibodies reactive
CC with a human HEV strain or natural mutants. The HEV and the proteins
CC HEV can be used in vaccines for immunising against HEV infection. The swine
CC swine HEV can also be used as a therapeutic treatment for infection by
CC other strains of HEV. The swine HEV can also be used for the production
CC of antibodies which can be used in therapy, detection and diagnosis. The
CC products can also be used for determining the susceptibility of cells or
CC organs to infection with swine HEV. The swine HEV is particularly useful
CC for the development of agents for the prevention, treatment and detection
CC of human HEV because it is not a human virus and thus can be handled both
CC experimentally and clinically without fear of severe infection and/or
CC contamination.
SQ Sequence 659 AA;

Query Match 46.3%; Score 82; DB 1; Length 659;
Best Local Similarity 68.8%; Pred. No. 2.31e+01;
Matches 11; Conservative 3; Mismatches 1; Indels 1; Gaps 1;

Db 1 MRRP-PLLLLMFLPYVPAP 20
2 MRRARFLLGLGVFLASVSF 22
QY 2 MRRARFLLGLGVFLASVSF 22

RESULT 5
ID R39308 standard; Protein: 659 AA.
AC R39308.
DT 14-FEB-1994 (first entry)
DE Mexican strain HEV ORF2 putative virus capsid protein.
KW Hepatitis E virus; vaccine; neutralising antibodies; infection;
KW block; open reading frame; antibodies.
OS Hepatitis E virus.
PN WO9314208-A.
PD 22-JUL-1993.
PF 19-JAN-1993; U00475.
PR 17-JAN-1992; US-822335.
PA (GENE-) GENELABS TECHNOLOGIES INC.
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
PI Bradley DM, Krawczynski KZ, Purdy MA, Reyes GR, Tam AW, Twu J;
DR WPI: 93-243223/30.
DR N-PSDB: 046814.
PT Antigen and antibody vaccines against hepatitis E virus infection
PT - contain peptide(s) derived from capsid protein C-terminal or
PT antibodies against protein
PS Disclosed: Fig 7; 43pp; English.
CC The sequence is that of the putative virus capsid protein encoded
CC by Mexican strain hepatitis E virus (HEV) open reading frame ORF2.
CC This protein or peptide fragments of it may be used in a vaccine
CC composition for immunising an individual against HEV. Antibodies
CC raised against these peptides can also be used in such vaccines.
SQ Sequence 659 AA;

Query Match 46.3%; Score 82; DB 1; Length 659;
Best Local Similarity 68.8%; Pred. No. 2.31e+01;
Matches 11; Conservative 3; Mismatches 1; Indels 1; Gaps 1;

Db 1 MRRP-PLLLLMFLPYVPAP 20
2 MRRARFLLGLGVFLASVSF 22
QY 2 MRRARFLLGLGVFLASVSF 22

RESULT 6
ID R38787 standard; Protein: 659 AA.
AC R38787;
DT 11-JAN-1994 (first entry)
DE HEV ORF2 protein.
KW Enterically transmitted non-A non-B hepatitis; ET-NANB;
OS Vaccine.
KM Hepatitis E virus Mexico strain.
FH Key Location/Qualifiers
FT peptide 225. .659
FT peptide /label= C2
FT peptide /label= SG3
FT peptide 612. .659
FT peptide /label= 406.3-2
PN MO9314116-A.
PD 22-JUL-1993.
PF 15-JUN-1993; U00459.
PR 17-JAN-1992; US-822335.
PR 01-MAY-1992; US-876941.
PA (GENE-) GENELABS TECHNOLOGIES INC.
PI (USSH) US SEC DEPT HEALTH.
PI Bradley DW, Carl M, Reyes GR, Tam AW;
DR N-PSDB: Q47130.
DR New immunogenic hepatitis E virus (HEV) peptide(s) - are from the
PT ORF1, ORF2 and ORF3 regions of HEV, useful as a vaccine against
PS HEV infection
PS Disclosure: Fig 8: 48bp; English.
CC Immunogenic hepatitis E virus (HEV) peptides are selected from the
CC ORF1, ORF2 and ORF3 regions of HEV. The peptides can be used in
CC vaccines to prevent infection by HEV. The antibodies can neutralise
CC and block HEV infection and can be used to prevent or treat HEV
CC infection. The peptides and antibodies can also be used as
CC diagnostic reagents.
SQ Sequence 659 AA:

Query Match 46.3%; Score 82; DB 1; Length 659;
Best Local Similarity 68.8%; Pred. No. 2.31e+01;
Matches 11; Conservative 3; Mismatches 1; Indels 1; Gaps 1;

Db 1 MRPR-PLILLFLFLP 15
||:| ||||| ||:|:
QY 2 MRARFPLLLGLVFLA 17

RESULT 7
ID W35827 standard; Protein: 659 AA.
AC W35827;
DT 26-FEB-1998 (first entry)
DE Hepatitis E virus Mexico strain protein from ORF2.
KM Hepatitis E virus; Burma; Mexico; immunoassay; peptide antigen;
KW antibody; diagnosis; HEV.
OS Hepatitis E virus - Mexico strain.
PN US5686239-A.
PD 11-NOV-1997.
PF 17-JUN-1988; 208997.
PR 09-MAY-1994; US-240049.
PR 17-JUN-1988; US-208997.
PR 11-APR-1989; US-336672.
PR 16-JUN-1989; US-367486.
PR 13-OCT-1989; US-420921.
PR 05-APR-1990; US-505888.
PR 05-APR-1991; US-681078.
PR 17-JAN-1992; US-822335.
PR 20-APR-1992; US-870985.
PR 01-MAY-1992; US-876941.
PA (GENE-) GENELABS TECHNOLOGIES INC.
PI Reyes GR, Tam AW, Yarbough PO;
DR WPI: 97-558132/51.
DR N-PSDB: T966960.
PT Diagnosis of hepatitis E virus Burma and Mexico strain infection -

PT by immunoassay with hepatitis E virus peptide antigens
PS Disclosure; Column 43-46; 36pp; English.
CC A method has been developed for detecting hepatitis E virus (HEV)
CC antibodies (Ab). The method comprises: (a) reacting a serum sample with
CC a HEV peptide antigen; and (b) examining the peptide for the presence
CC of bound Ab, where the presence of bound Ab indicates the presence of
CC HEV Ab. The present sequence represents the protein from the open
CC reading frame, ORF2, from HEV Mexico strain. The method can be used to
CC diagnose infection with the enterically transmitted non-A/non-B viral
CC hepatitis agent HEV, specifically the HEV Burma and Mexico strains.
SQ Sequence 659 AA:

Query Match 46.3%; Score 82; DB 1; Length 659;
Best Local Similarity 68.8%; Pred. No. 2.31e+01;
Matches 11; Conservative 3; Mismatches 1; Indels 1; Gaps 1;

Db 1 MRPR-PLILLFLFLP 15
||:| ||||| ||:|:
QY 2 MRARFPLLLGLVFLA 17

RESULT 8
ID R96090 standard; Protein: 660 AA.
AC R96090;
DT 06-AUG-1996 (first entry)
DE Hepatitis E virus (Mexico strain) capsid protein.
KM HEV; enterically-transmitted non-A/non-B hepatitis virus; vaccine;
KW diagnosis; antigen; Spodoptera frugiperda; Sf9; insect;
KW baculovirus; capsid.
OS Hepatitis E virus Mexico strain.
PN WO9612807-A2.
PD 02-MAY-1996.
PF 23-OCT-1995; U13703.
PR 24-OCT-1994; US-327952.
PR 13-OCT-1995; US-542634.
PA (GENE-) GENELABS TECHNOLOGIES INC.
PI Fuerst TR, McAttee CP, Yarbough PO, Zhang Y;
PI WPI: 96-230608/23.
DR N-PSDB: T27108.
DR Hepatitis E virus (HEV) antigens derived from ORF 2 - useful as
PT diagnostic reagents for determining HEV infection and in vaccines
PS Disclosure: Page 80-82; 125pp; English.
CC The putative capsid protein (R96090) of hepatitis E virus (HEV)
CC Mexico strain is encoded by ORF-2 (T27108) of the virus. PCR
CC amplification of ORF-2 allows prodn. of capsid protein or of
CC C-terminal regions of the capsid protein (see also R96092, R96094
CC and R96096) and expression in Spodoptera frugiperda Sf9 insect cells
CC using a baculovirus vector provides recombinant C-terminal regions
CC (see also R96102 and R96104) useful as diagnostic reagents and in
CC vaccines. The HEV Burma strain capsid protein (R96089) may
CC similarly be used.
SQ Sequence 660 AA:

Query Match 46.3%; Score 82; DB 1; Length 660;
Best Local Similarity 68.8%; Pred. No. 2.31e+01;
Matches 11; Conservative 3; Mismatches 1; Indels 1; Gaps 1;

Db 1 MRPR-PLILLFLFLP 15
||:| ||||| ||:|:
QY 2 MRARFPLLLGLVFLA 17

RESULT 9
ID W50882 standard; Protein: 105 AA.
AC W50882;
DT 09-SEP-1998 (first entry)
DE Amino acid sequence of mouse mpf4 protein.
KM Mouse; mpf4 gene; chemokine; anti-inflammatory; mGAP3; mGCKine;
KW hGCKine; Chrl9kline; cancer; degenerative condition; antibody;
KW immuno assay; forensic assay; in situ assay.
OS Mus sp.
FH Key Location/Qualifiers
FT Peptide 1. .39

FT /note="signal peptide"
 FT Protein 40.105
 FT /note="mature protein"
 PN W09814581-A1.
 PD 09-APR-1998.
 PF 02-OCT-1997; U17122.
 PR 28-AUG-1997; US-058007.
 PR 02-OCT-1996; US-027242.
 PR 09-OCT-1996; US-028042.
 PA (SCHE) SCHERING CORP.
 PI Hedrick JA, Zlotnik A;
 DR WPI: 98-240086/21.
 DR N-PSDB: V07111.
 PT Mouse and human CC and CXC chemokine(s) - useful to modulate
 PT physiology or development of cells to treat, e.g. cancerous or
 PT degenerative conditions
 PS Claim 1; Page 75; 88pp; English.
 CC This is the amino acid sequence of the mouse mpf4 protein, a chemokine
 CC with anti-inflammatory properties. It is used in the method of the
 CC invention where mouse and human CC and CXC chemokines, designated
 CC mpf4, mcrp3, mckine, hckine and Chrlp9k are used to modulate the
 CC physiology or the development of cells to treat, cancerous or
 CC degenerative conditions. The chemokines can also be used to generate
 CC antibodies, useful in immunoassays to measure chemokines, while the
 CC nucleic acid sequences may be used as components in forensic assays or
 CC in situ assays to detect chromosomal abnormalities.
 SQ Sequence 105 AA;

Query Match 45.8%; Score 81; DB 1; Length 105;
 Best Local Similarity 55.6%; Pred. No. 2.73e+01;

Matches 10; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Db 10 LNPSELLGLLFLPAV 27
 : : |||||:|:|
 Oy 2 MRARFPLLLGLVFLASV 19

RESULT 10
 ID W62834 standard; Peptide: 614 AA.
 AC W62834;
 DT 27-OCT-1998 (first entry)
 DE Arachis hypogaea antimicrobial protein.
 KW antimicrobial protein; infestation; control.
 OS Arachis hypogaea.
 PN W09827805-A1.
 PD 02-JUL-1998.
 PF 22-DEC-1997; AU-004275.
 PR 20-DEC-1996; AU-004275.
 PA (RETR.) COOP RES CENT TROPICAL PLANT PATHOLOGY.
 PI Bower NI, Goulter KC, Green, JL, Manners JM, Marcus JP;
 DT 29-DEC-1997 (first entry)
 DE Novel anti-microbial protein from e.g. Macadamia integrifolia -
 PT useful for controlling microbial infestations of plants or mammals
 PS Claim 1; Page 55-57; 96pp; English.
 CC The sequence is that of an antimicrobial protein which can
 CC be used to control microbial infestations in plants and mammalian
 CC animals.
 SQ Sequence 614 AA;

Query Match 45.8%; Score 81; DB 1; Length 614;
 Best Local Similarity 60.9%; Pred. No. 2.73e+01;

Matches 14; Conservative 4; Mismatches 3; Indels 2; Gaps 2;

Db 1 MGRVSPMLLLGLIVLASVAT 23
 ||:| |||||:|:|
 Oy 2 MRARF-PL-LILGLVFLASVSVS 22

RESULT 11
 ID W22149 standard; Protein: 614 AA.
 AC W22149;
 DT 29-DEC-1997 (first entry)
 DE Peanut allergen Ara hi.

KW Peanut; seed storage protein; allergen; allergy; hypersensitivity;
 KW vaccine; anaphylactic shock; immunotherapy; therapy;
 KW monoclonal antibody; ELISA; analysis; Ara hi.
 OS Arachis hypogaea strain Florunner.
 FH Key .Location/Qualifiers
 FT Peptide 1..22
 FT /label= sig-peptide
 FT Protein 23..614
 FT /label= Mat-protein
 FT Modified_site 521..523
 FT /note="N-glycosylation site"
 PN W09724139-A1.
 PD 10-JUL-1997.
 PF 23-SEP-1996; U15222.
 PR 04-MAR-1996; US-610424.
 PR 29-DEC-1995; US-009455.
 PA (UYAR-) UNIV ARKANSAS.
 PI Bannon GA, Burks AW, Cockrell G, Helm RM, Stanley JS;
 DR WPI: 97-363453/33.
 DR N-PSDB: T76612.
 PT Peanut allergens Ara hi and Ara hii - used for vaccination and in
 PT two-site monoclonal antibody based ELISA
 PS Claim 31; Page 169; 354pp; English.
 CC This polypeptide comprises major peanut allergen Ara hi (W22149).
 CC Its sequence was deduced from cDNA clone p17 (T76612), isolated
 CC from peanut seed cDNA using a primer (see T76616) based on an
 CC isolated Ara hi peptide (see W24206). The sequence shows
 CC significant homology with the vicilin family of seed storage
 CC proteins of other legumes. The allergen is recognised by serum
 CC IgE from a large proportion of individuals with peanut
 CC hypersensitivity. Ara hi and Ara hii (see W24164) can be used to
 CC raise monoclonal antibodies which are used in a specific two-site
 CC MAb ELISA for the detection of Ara hi or Ara hii (claimed). IgE-
 CC binding Ara hi antigen epitopes (see W24165-87) may be used in
 CC vaccines to protect against allergic reactions to peanut allergens,
 CC e.g. anaphylactic shock.
 SQ Sequence 614 AA;

Query Match 45.8%; Score 81; DB 1; Length 614;
 Best Local Similarity 60.9%; Pred. No. 2.73e+01;

Matches 14; Conservative 4; Mismatches 3; Indels 2; Gaps 2;

Db 1 MGRVSPMLLLGLIVLASVAT 23
 ||:| |||||:|:|
 Oy 2 MRARF-PL-LILGLVFLASVSVS 22

RESULT 12
 ID W22150 standard; Protein: 626 AA.
 AC W22150;
 DT 29-DEC-1997 (first entry)
 DE Peanut allergen Ara hi.
 KW Peanut; seed storage protein; allergen; allergy; hypersensitivity;
 KW vaccine; anaphylactic shock; immunotherapy; therapy;
 KW monoclonal antibody; ELISA; analysis; Ara hi.
 OS Arachis hypogaea strain Florunner.
 FH Key .Location/Qualifiers
 FT Peptide 1..22
 FT /label= sig-peptide
 FT Protein 23..626
 FT /label= Mat-protein
 FT Modified_site 521..523
 FT /note="N-glycosylation site"
 PN W09724139-A1.
 PD 10-JUL-1997.
 PF 23-SEP-1996; U15222.
 PR 04-MAR-1996; US-610424.
 PR 29-DEC-1995; US-009455.
 PA (UYAR-) UNIV ARKANSAS.
 PI Bannon GA, Burks AW, Cockrell G, Helm RM, Stanley JS;
 DR WPI: 97-363453/33.
 DR N-PSDB: T76613.
 PT Peanut allergens Ara hi and Ara hii - used for vaccination and in

Query	Match	Score	DB	Length	Gaps
1	MRGRVPLMLLGLVILVASVAT	23			
2	MRAR-PL-LLLGLVFLASVS	22			
3	MRAR-PL-LLLGLVFLASVS	22			
4	MRAR-PL-LLLGLVFLASVS	22			
5	MRAR-PL-LLLGLVFLASVS	22			
6	MRAR-PL-LLLGLVFLASVS	22			
7	MRAR-PL-LLLGLVFLASVS	22			
8	MRAR-PL-LLLGLVFLASVS	22			
9	MRAR-PL-LLLGLVFLASVS	22			
10	MRAR-PL-LLLGLVFLASVS	22			
11	MRAR-PL-LLLGLVFLASVS	22			
12	MRAR-PL-LLLGLVFLASVS	22			
13	MRAR-PL-LLLGLVFLASVS	22			
14	MRAR-PL-LLLGLVFLASVS	22			
15	MRAR-PL-LLLGLVFLASVS	22			
16	MRAR-PL-LLLGLVFLASVS	22			
17	MRAR-PL-LLLGLVFLASVS	22			
18	MRAR-PL-LLLGLVFLASVS	22			
19	MRAR-PL-LLLGLVFLASVS	22			
20	MRAR-PL-LLLGLVFLASVS	22			
21	MRAR-PL-LLLGLVFLASVS	22			
22	MRAR-PL-LLLGLVFLASVS	22			
23	MRAR-PL-LLLGLVFLASVS	22			
24	MRAR-PL-LLLGLVFLASVS	22			
25	MRAR-PL-LLLGLVFLASVS	22			
26	MRAR-PL-LLLGLVFLASVS	22			
27	MRAR-PL-LLLGLVFLASVS	22			
28	MRAR-PL-LLLGLVFLASVS	22			
29	MRAR-PL-LLLGLVFLASVS	22			
30	MRAR-PL-LLLGLVFLASVS	22			
31	MRAR-PL-LLLGLVFLASVS	22			
32	MRAR-PL-LLLGLVFLASVS	22			
33	MRAR-PL-LLLGLVFLASVS	22			
34	MRAR-PL-LLLGLVFLASVS	22			
35	MRAR-PL-LLLGLVFLASVS	22			
36	MRAR-PL-LLLGLVFLASVS	22			
37	MRAR-PL-LLLGLVFLASVS	22			
38	MRAR-PL-LLLGLVFLASVS	22			
39	MRAR-PL-LLLGLVFLASVS	22			
40	MRAR-PL-LLLGLVFLASVS	22			
41	MRAR-PL-LLLGLVFLASVS	22			
42	MRAR-PL-LLLGLVFLASVS	22			
43	MRAR-PL-LLLGLVFLASVS	22			
44	MRAR-PL-LLLGLVFLASVS	22			
45	MRAR-PL-LLLGLVFLASVS	22			
46	MRAR-PL-LLLGLVFLASVS	22			
47	MRAR-PL-LLLGLVFLASVS	22			
48	MRAR-PL-LLLGLVFLASVS	22			
49	MRAR-PL-LLLGLVFLASVS	22			
50	MRAR-PL-LLLGLVFLASVS	22			
51	MRAR-PL-LLLGLVFLASVS	22			
52	MRAR-PL-LLLGLVFLASVS	22			
53	MRAR-PL-LLLGLVFLASVS	22			
54	MRAR-PL-LLLGLVFLASVS	22			
55	MRAR-PL-LLLGLVFLASVS	22			
56	MRAR-PL-LLLGLVFLASVS	22			
57	MRAR-PL-LLLGLVFLASVS	22			
58	MRAR-PL-LLLGLVFLASVS	22			
59	MRAR-PL-LLLGLVFLASVS	22			
60	MRAR-PL-LLLGLVFLASVS	22			
61	MRAR-PL-LLLGLVFLASVS	22			
62	MRAR-PL-LLLGLVFLASVS	22			
63	MRAR-PL-LLLGLVFLASVS	22			
64	MRAR-PL-LLLGLVFLASVS	22			
65	MRAR-PL-LLLGLVFLASVS	22			
66	MRAR-PL-LLLGLVFLASVS	22			
67	MRAR-PL-LLLGLVFLASVS	22			
68	MRAR-PL-LLLGLVFLASVS	22			
69	MRAR-PL-LLLGLVFLASVS	22			
70	MRAR-PL-LLLGLVFLASVS	22			
71	MRAR-PL-LLLGLVFLASVS	22			
72	MRAR-PL-LLLGLVFLASVS	22			
73	MRAR-PL-LLLGLVFLASVS	22			
74	MRAR-PL-LLLGLVFLASVS	22			
75	MRAR-PL-LLLGLVFLASVS	22			
76	MRAR-PL-LLLGLVFLASVS	22			
77	MRAR-PL-LLLGLVFLASVS	22			
78	MRAR-PL-LLLGLVFLASVS	22			
79	MRAR-PL-LLLGLVFLASVS	22			
80	MRAR-PL-LLLGLVFLASVS	22			
81	MRAR-PL-LLLGLVFLASVS	22			
82	MRAR-PL-LLLGLVFLASVS	22			
83	MRAR-PL-LLLGLVFLASVS	22			
84	MRAR-PL-LLLGLVFLASVS	22			
85	MRAR				

CC The secretin receptor was encoded by a DNA sequence of rat origin,
CC contained in rat/mouse hybridoma NG108-15. The DNA sequence was
CC obtd. from a cDNA library derived from NG108-15 cells. Expression
CC in a suitable host allows prodn. of the receptor protein. The
CC secretin receptor protein encoded by this gene may be used in basic
CC research and in clinical tests, and is available in high yield.
SQ Sequence 449 AA;

Query Match 45.2%; Score 80; DB 1; Length 449;
Best Local Similarity 47.4%; Pred. No. 3.21e+01;
Matches 9; Conservative 7; Mismatches 3; Indels 0; Gaps 0;

Db 5 MRPRSLILRLILITKAA 23
|||:|||||:|:|:|
Qy 2 MRARPLILGLVFLASVS 20

RESULT 14
ID W96638 standard; Protein: 246 AA.
AC W96638;
DT 31-MAR-1999 (first entry)
DE H. pylori GHP0 343 protein.
KW GHP0 protein; Helicobacter infection; gastroduodenal disease; gastritis;
KW peptic ulcer disease.
OS Helicobacter pylori.
PN W09843478-A1.
PD 08-OCT-1998.
PF 01-APR-1998: 006371.
PR 29-JUL-1997: US-902615.
PR 01-APR-1997: US-833457.
PR 24-JUN-1997: US-881227.
PA (HUMA-) HUMAN GENOME SCI INC.
PA (INMR) MERIEUX ORAVAX PASTEUR MERIEUX SERUMS.
PI Al-Gazawi A, Kleanthous H, Miller C, Oomen RP, Tomb J;
DR WPI: 98-542293/46.
DR N-PSDB: X14357.
PT New Isolated Helicobacter polynucleotides - used to develop products
PT for the diagnosis, prevention and treatment of Helicobacter
PT infections and gastrointestinal diseases
PS Claim 8: Page 1304-1306: 2054pp: English.
CC This sequence represents a Helicobacter pylori GHP0 protein of the
CC invention. The polypeptides can be used for preventing or treating
CC Helicobacter infections, and gastroduodenal diseases associated with
CC these infections, including acute, chronic, and atrophic gastritis, and
CC peptic ulcer diseases, e.g. gastric and duodenal ulcers. They can also be
CC used for the production of antibodies. The products can also be used for
CC detection and diagnosis.
SQ Sequence 246 AA;

Query Match 43.5%; Score 77; DB 1; Length 246;
Best Local Similarity 52.9%; Pred. No. 5.23e+01;
Matches 9; Conservative 6; Mismatches 1; Indels 1; Gaps 1;

Db 177 PLFLMG-IFLSKISVSX 192
|||:|:|:|:|:|:|:|:|
Qy 7 PLILGLVFLASVSXSF 23

RESULT 15
ID W93390 standard; Protein: 660 AA.
AC W93390;
DT 11-JUN-1999 (first entry)
DE Human HEV ORF 2 protein from strain Madras.
KW Swine hepatitis E virus, HEV; cross-reaction; antibody; human; therapy;
KW vaccine; Immunuse; Infection; detection; diagnosis; prevention.
OS Hepatitis E virus?
PN W09904029-A2.
PD 28-JAN-1999.
PF 17-JUL-1998: U14665.
PR 18-JUL-1997: US-053069.
PR (USSH) US DEPT HEALTH & HUMAN SERVICES.
PI Emerson SU, Meng X, Purcell RH;
DR WPI: 99-132270/11.

